-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tumor immunotherapy is currently a hot spot in the development of new anti-tumor drugs.
In order to improve the scientificity and robustness of the determination of immune-related adverse events in clinical trials of anti-tumor therapy, improve the quality of safety data such as instructions, and strengthen the protection of patients participating in trials and post-marketing drugs, the industry has investigated and initially solicited expert opinions.
We sincerely welcome valuable comments and suggestions from all walks of life on the solicitation draft, and timely feedback to us for follow-up improvement
Please send your feedback to the mailbox of the following contact:
Contact: Lu Jun, Zhou Ming
Contact: lvj@cde.
Thank you for your participation and great support
Drug Evaluation Center of the State Drug Administration
November 26, 2021
1 "Technical Guidelines for Evaluation of Immune-related Adverse Events in Anti-tumor Therapy (Draft for Solicitation of Comments)".
1 "Technical Guidelines for Evaluation of Immune-related Adverse Events in Anti-tumor Therapy (Draft for Solicitation of Comments)".
2 "Technical Guidelines for Evaluation of Immune-related Adverse Events in Anti-tumor Therapy (Draft for Comment)" feedback form.
docx